Eli Lilly & Co. (NYSE:LLY)

Short Sellers Can’t Make Up Their Minds on Major Pharma

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

JPMorgan Likes Big Cap Pharmaceutical Stocks as Market Volatility Jumps

For years pharmaceuticals were one group considered good for “widows and orphans” as they provided safety and consistent and rising income via dividends. Then came the brutal 2016 political season wherein ...
Read Full Story »

Eli Lilly Cruises Through Q4 Earnings

Eli Lilly and Co. (NYSE: LLY) reported its fourth-quarter financial results before the markets opened on Wednesday. The company posted $1.14 in earnings per share (EPS) and $6.16 billion in ...
Read Full Story »

Major Pharma Short Interest Keeps Climbing

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

SunTrust Bullish on Blue Chip Large-Cap Pharmaceuticals: 4 to Buy Now

Some of last year's biggest laggards are starting to look like this year's winners out of the gate here in January. While health care was basically in line with the ...
Read Full Story »

Top Analyst Upgrades and Downgrades: Apple, BHP Billiton, CBS, Eli Lilly, GE, Halliburton, IBM, Schlumberger, Verizon and More

Stocks were lower on Monday, but perhaps not as bad as many might have worried about considering the government shutdown. What investors have to consider is that prior to the ...
Read Full Story »

Top Analyst Upgrades and Downgrades: Amazon, Boeing, Chesapeake Energy, Eli Lilly, Gilead, Micron, NVIDIA, P&G, Qualcomm and More

Stocks were indicated higher on Tuesday morning, for basically more of the same in gains almost every day of the new year. Now that the bull market is nearly nine ...
Read Full Story »

Major Pharma Short Interest Takes a Plunge

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

20 More Biopharma Catalysts Coming in 2018

Over the course of 2017, biopharmaceutical companies more or less kept pace with the markets, ending up with a return just a little higher than the S&P 500. But going in ...
Read Full Story »

Top Analyst Upgrades and Downgrades: Cheniere, Cisco, Eli Lilly, Intel, Kroger, Nokia, Rite Aid, Roku, Teva, Tyson, Walgreens and More

Stocks have risen in each of the first three days of 2018, hitting new high after new high. The Dow Jones Industrial Average rose over 25% in 2017 and is ...
Read Full Story »

More and More Short Sellers Raising the Stakes in Major Pharma

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Short Sellers Can’t Make Up Their Minds on Major Pharma

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Short Sellers Back Way Off Major Pharma

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Short Sellers Hike Bets in Major Pharma

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

13 Spin-Offs Set to Radically Change Top Companies in 2017 and 2018

The bull market is now closer to nine years old than it is eight, and the great stock market rally of 2017 has continued to amaze skeptics and bulls alike. ...
Read Full Story »